A phase II clinical study of the WT1 cancer vaccine, developed by SELLAS Life Sciences Group, showed increased median overall survival in patients with malignant pleural mesothelioma.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe